ACT News 215.06 06/18/2014 04:22:34 Actavis Inc (ACT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Actavis Inc (ACT) 215.06 $ACT

Actavis' shareholders approves planned acquisition of Forest for about USD25bn in cash and stock
M2 - 29 mins ago
Specialist pharmaceutical company Actavis (NYSE:ACT) stated on Tuesday that all proposals related to its planned acquisition of Forest Laboratories (NYSE:FRX) were approved by their respective shareholders at the recent shareholder meetings.

Actavis and Forest Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Forest
Business Wire - Tue Jun 17, 3:17PM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that, at shareholder meetings held today, all proposals related to Actavis' planned acquisition of Forest were approved by both Actavis' and Forest's shareholders.

Cardax Appoints Former Novartis, Bristol-Myers Squibb, and Boehringer Ingelheim Executives as Directors
Business Wire - Tue Jun 17, 7:01AM CDT
Cardax, Inc. ("Cardax" (OTCQB:CDXI) announced today the appointment of George W. Bickerstaff, former CFO of Novartis Pharma AG (NYSE:NVS), Tamar D. Howson, former senior business development executive at Bristol-Myers Squibb (NYSE:BMY) and SmithKline Beecham, and Terence A. Kelly, Ph.D., former senior Boehringer Ingelheim anti-inflammatory R&D executive and current CEO of CoMentis, as independent members of its Board of Directors. They will join current Executive Chairman Nicholas Mitsakos, independent director Frank Herringer, and Cardax CEO David G. Watumull on the Cardax Board.

Actavis Strives To Reduce Borrowing Costs
at Investor's Business Daily - Fri Jun 13, 5:48PM CDT
Generic, branded and biosimilar drugmaker Actavis (ACT) may be well-known among investors as a company that has used large acquisitions as one method to boost its earnings and sales sharply. Yet less attention perhaps has been paid to its savvy...

Will Forest Labs Retain Namenda Market Share? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 11:00AM CDT
Forest Laboratories, Inc. (FRX) has postponed the final phase of switching to late 2014 and intends to continue marketing Namenda IR till the fall of 2014.

Actavis Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Forest Laboratories Senior Notes
PR Newswire - Thu Jun 12, 5:16PM CDT
Actavis plc (NYSE: ACT) today announced that Forest Laboratories, Inc. (NYSE: FRX) has received valid consents (the "Requisite Consents" from holders of a majority in aggregate principal amount of each series of Forest's securities listed in the table below (the "FRX Notes" to the elimination of Forest's contractual registration rights obligations with respect to each series of FRX Notes (the "Proposed Amendments" (collectively, the "Consent Solicitations". As consideration for the Requisite Consents, Actavis will fully, unconditionally and irrevocably guarantee (each, a "ACT Guarantee" and, together, the "ACT Guarantees" each series of FRX Notes, subject to the closing of Actavis' pending acquisition (the "Acquisition" of Forest and certain other customary conditions. The terms and conditions of the Consent Solicitations are described in the Offering Memorandum/Consent Solicitation Statement, dated May 22, 2014 (as may be amended or supplemented from time to time, the "Consent Solicitations Statement".

Forest Laboratories, Inc. Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Certain of its Senior Notes
Business Wire - Thu Jun 12, 4:00PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it had received valid consents (the "Requisite Consents" from holders of a majority in aggregate principal amount of each series of its securities listed in the table below (the "FRX Notes" to the elimination of Forest's contractual registration rights obligations with respect to each series of FRX Notes (the "Proposed Amendments" (collectively, the "Consent Solicitations". As consideration for the Requisite Consents, Actavis plc (NYSE:ACT) will fully, unconditionally and irrevocably guarantee (each, a "ACT Guarantee" and, together, the "ACT Guarantees" each series of FRX Notes, subject to the closing of Actavis' pending acquisition (the "Acquisition" of Forest and certain other customary conditions. The terms and conditions of the Consent Solicitations are described in the Offering Memorandum/Consent Solicitation Statement, dated May 22, 2014 (as may be amended or supplemented from time to time, the "Consent Solicitations Statement".

VIVUS Files Lawsuit Against Actavis for Infringement of Qsymia Patents
Marketwire - Thu Jun 12, 3:33PM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Actavis Laboratories FL, Inc., Actavis, Inc., and Actavis PLC, collectively referred to as Actavis.

Worldwide IV Iron Drugs Industry Analysis and 2018 Forecasts New Research Study Available at MarketReportsOnline.com
PRWeb - Thu Jun 12, 4:03AM CDT
Intravenous (IV) treatment, in a broad sense, covers all the types of medications delivered intravenously, i.e. directly into the vein, through intravenous drip. Compared to the other routes of infusing medications, the intravenous route is the fastest way to deliver fluids and medications throughout the body. Also, this method ensures 100% bioavailability, which means that the chemicals delivered are fully absorbed by the body. The first iron product for intravenous use was high-molecular-weight iron dextran. Some of the major areas of IV iron application include gynecology, gastroenterology, oncology and surgeries. Hemoglobin, Ferritin, Transferrin, and Hepcidin are major molecules which are critical in the function and regulation of iron.

Today's Top Performers In Health Care
at The Street - Wed Jun 11, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.

Actavis to close USD3.7bn senior unsecured notes on 19 June 2014
M2 - Wed Jun 11, 4:51AM CDT
Pharmaceutical company Actavis (NYSE:ACT) said on Tuesday that its Actavis Funding SCS indirect subsidiary has priced its total aggregate offering of USD3.7bn senior unsecured notes 19 June 2014.

Actavis, BitAuto Among Leading World Stocks In Bases
at Investor's Business Daily - Tue Jun 10, 5:50PM CDT
Six of the 10 stocks listed on the Top World Stocks list in Tuesday's IBD are pecking away at new highs. Some are still in buying range after clearing bases. Four others are building bases. One minor catch: They are all late-stage patterns. Late...

Actavis Prices $3.7 Billion of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 4:19PM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, priced a private debt offering of $500 million of 1.300% senior unsecured notes due 2017, $500 million of 2.450% senior unsecured notes due 2019, $1.2 billion of 3.850% senior unsecured notes due 2024 and $1.5 billion of 4.850% senior unsecured notes due 2044, for a total offering of $3.7 billion in aggregate principal amount. The offering is expected to close on June 19, 2014, subject to market conditions and other factors.

Lannett In Buying Range After Breakout From Cup Base
at Investor's Business Daily - Tue Jun 10, 3:35PM CDT
Generic-drug maker Lannett (LCI) is in buying range following a breakout from a cup-without-handle base. The stock is within the 5% buy area after succeeding Monday in its third try to clear the 46.61 buy point. The previous attempts last Thursday...

Fitch Rates New Actavis Bonds 'BBB-'; Outlook Stable
Business Wire - Tue Jun 10, 9:55AM CDT
Fitch Ratings has assigned a 'BBB-' rating to new senior unsecured bonds to be issued by an indirect subsidiary of Actavis plc (NYSE: ACT). Fitch has also assigned a 'BBB-' Issuer Default Rating (IDR) to Actavis Funding SCS, the issuer of the bonds, and Warner Chilcott Limited. ACT's IDR is 'BBB-', with a Stable Outlook. A full list of ratings for ACT follows at the end of this release.

Actavis Announces Offering of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 7:48AM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, is privately offering three, five, ten and thirty year senior unsecured notes.

Actavis Finalizes Agreement Related to Asacol® HD Patent Challenge Litigation
PR Newswire - Mon Jun 09, 4:54PM CDT
Actavis plc (NYSE: ACT) today announced that it has finalized its previously announced agreement with Zydus Pharmaceuticals USA Inc. to settle all outstanding patent litigation related to Zydus' generic version of Asacol® HD (mesalamine) delayed-release tablets. The terms of the agreement are unchanged from those disclosed by the companies in December 2013.

Why I Like Actavis Stock
Mohsin Saeed, The Motley Fool - Motley Fool - Mon Jun 09, 1:12PM CDT
Investments in small capitalization biotechnology companies are fraught with risks. Most bio-techs rely on a single or a few trial candidates to determine their entire valuations. With little or no revenues, the downside to these stocks is immense. A...

Forest Laboratories, Inc. Extends Expiration Time of Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Business Wire - Mon Jun 09, 7:01AM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it has extended the expiration date of its consent solicitations (the "Consent Solicitations" to eliminate existing registration rights obligations with respect to its outstanding debt securities listed in the table below (the "FRX Notes" in exchange for the offer by Actavis plc (NYSE: ACT) to guarantee (the "ACT Guarantees" each of the FRX Notes. The Consent Solicitations were originally scheduled to expire at 5:00 p.m., New York City time, on June 6, 2014. The expiration date of the Consent Solicitations has been extended until 5:00 p.m., New York City time, on June 12, 2014.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Biohaven's BHV-1530 Data Earns a Careful Investor Look

Updated Category News Views 19

Thirty heavily treated cancer patients can make a molecule look brilliant or merely lucky, and BHV-1530 is still living in that uncomfortable early-stage gap. Biohaven presented Phase 1 results at ENA 2026 that deserve real attention, particularly because the responses showed up in patients with few attractive remaining options. But this is not the moment to confuse a...

Continue Reading
Yunnan Tin’s AI Materials Push Has Real Operating Teeth

Updated Category News Views 66

Tin rarely gets the spotlight until the machinery behind modern computing starts demanding more of it. Yunnan Tin Group is making the sensible case that this unglamorous metal can matter a great deal in semiconductors, artificial intelligence infrastructure and new-energy hardware. There is plenty of corporate ambition wrapped around that case, naturally, but a few...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 21

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
Tongwei's 846 MW Romania Deal Tests Solar Supply Scale

Updated Category News Views 74

Eight hundred forty-six megawatts of panels do not quietly roll out the factory gate. Tongwei’s supply agreement with Rezolv Energy for Romania’s Dama Solar project is a hefty piece of utility-scale solar business, and the first truckload has already left Tongwei’s Nantong facility. That matters more than another polished signing-ceremony photo: equipment is moving,...

Continue Reading
NVE Revenue Pull-Forward Raises Hard Investor Questions

Updated Category News Views 50

A Quarter Can Look Great Until It Doesn’t NVE investors got a nasty lesson in revenue timing, the sort that makes even old hands check the fine print twice. On July 22, 2026, the company reported sequential revenue growth of 43% and net-income growth of 23%. The next trading day, shares vaulted $47.53, or 54%. Then came October, and the floor gave way: NVE reported that...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 87

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
Brightstar Picks Warsop for Its Next CEO Chapter Ahead

Updated Category News Views 31

A Handoff With Plenty Riding on the Rails A lottery supplier changing captains is not usually fireworks, but this one deserves a hard look. Brightstar Lottery has named Thomas Warsop to replace Vince Sadusky as chief executive officer and board member effective January 1, 2027. Sadusky is retiring from both posts on that date. The company is telegraphing an orderly baton...

Continue Reading
T. Rowe Price Expands Teams Across 12 Fund Strategies

Updated Category News Views 49

A Quiet Personnel Shift With Real Stakes Twelve strategy changes may sound like administrative wallpaper, but asset managers live and die by who makes the calls. T. Rowe Price is broadening portfolio-management teams across equity and fixed-income offerings while insisting that each strategy's philosophy, process, and risk limits remain intact. Fine. That is the stated...

Continue Reading
Abbe Lane Estate Puts Jewelry Demand on Full Display

Updated Category News Views 101

Glamour Is Walking Back Into the Auction Room Abbe Lane’s jewelry is not being offered as a vague nostalgia exercise; it is arriving with dates, a setting, and a clear split between two December sales. John Moran Auctioneers will lead with The Estate of Abbe Lane on Wednesday, December 9, 2026, at 10:00 a.m. PST, then follow with its Jewelry & Watches auction on...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 217

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading

Top 5 Most Recently Viewed Articles

Navigating Component Obsolescence: Key Trends and Insights

Updated Category News Views 170

Understanding Component Obsolescence in Today's Market In the rapidly evolving world of semiconductors and electronic components, tracking obsolescence has become crucial. Bill Bradford, President of Flip Electronics, sheds light on these trends that are shaping the industry as we move towards 2026. The market has seen a significant shift, primarily due to increasing...

Continue Reading
Exploring Class Action Claims Against iLearningEngines - AILE

Updated Category News Views 181

Understanding the Class Action Lawsuit Against iLearningEngines Faruqi & Faruqi, LLP, a prominent name in securities litigation, is taking steps to inform investors about a significant class action lawsuit related to iLearningEngines, Inc. The law firm, known for its commitment to protecting investors' rights, has set a deadline for potential lead plaintiffs in this case....

Continue Reading
Key Stock Movements: Sanmina and other Performers Soar

Updated Category News Views 440

Key Stock Movements on Tuesday U.S. stocks exhibited mixed performance with the Dow Jones index declining around 100 points. Despite the overall market volatility, several companies reported substantial improvements in their stock values on Tuesday. Sanmina Corporation Performance Sanmina Corporation (NASDAQ: SANM) saw an impressive rise in its stock during Tuesday's...

Continue Reading
Segal Trials' Innovations in Schizophrenia Treatment with LB-102

Updated Category News Views 303

Segal Trials Advances Schizophrenia Research with LB-102 Segal Trials is making significant strides in the field of schizophrenia research, focusing on the innovative treatment method involving LB-102. This investigational drug, which is a potential first-in-class benzamide antipsychotic, is being evaluated in a Phase 2 trial. The main goal of this study is to assess the...

Continue Reading
Innovative Vehicle Safety System Promises Improved Driver Focus

Updated Category News Views 237

Introduction to an Innovative Safety Solution In today's fast-paced world, driving distractions can have serious consequences. An inventive mind has created a new device called SAFE DRIVE, aimed at enhancing driver concentration and reducing the risks associated with smartphone usage while driving. Concept Behind SAFE DRIVE The SAFE DRIVE invention is designed with a...

Continue Reading